Cancer Family
Secondary Malignant Neoplasm
CI-CAN-00000346SMNExplore in graph →
4,275 active trials56 approved drugs532 evidence items
- NCIt
- C4968
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000346SMNExplore in graph →
Clinical trials
14,674 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05922579 | A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NET | terminated | — | 191 | IpsenINDUSTRY | 1 | Feb 29, 2024 | clinicaltrials |
| NCT03812562 | Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection | terminated | Early Phase 1 | 2 | Northwestern UniversityOTHER | 1 | Feb 21, 2024 |
| NCT04624113 | Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | terminated | Phase 1 | 13 | Washington University School of MedicineOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT03345784 | Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers | terminated | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 2 | Feb 20, 2024 | clinicaltrials |
| NCT03997448 | Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149 | terminated | Phase 2 | 3 | Nataliya UbohaOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04461600 | A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer(TENACITY) | terminated | Phase 2 | 18 | Ayala Pharmaceuticals, Inc,INDUSTRY | 5 | Feb 12, 2024 | clinicaltrials |
| NCT04826432 | Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis(PASIREOCHIP) | terminated | Phase 2 | 6 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 8 | Georgetown UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03606486 | Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer | terminated | N/A | 52 | University of WashingtonOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | terminated | Phase 1 / Phase 2 | 25 | pharmaand GmbHINDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT03709771 | Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease | terminated | — | 2 | Vanderbilt University Medical CenterOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT03420521 | Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors | terminated | Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT04046887 | Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) | terminated | Phase 1 | 14 | Patrick Joseph Loehrer Sr.OTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | terminated | Phase 1 | 10 | University of FloridaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03499678 | Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA | terminated | — | 81 | HKGepitherapeuticsINDUSTRY | 1 | Dec 22, 2023 | clinicaltrials |
| NCT04634825 | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer | terminated | Phase 2 | 62 | MacroGenicsINDUSTRY | 7 | Dec 20, 2023 | clinicaltrials |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Fusion Pharmaceuticals Inc.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT04341740 | Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma(WindMIL-001) | terminated | N/A | 6 | University of OklahomaOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | terminated | Phase 1 | 14 | IpsenINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT04452396 | CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia | terminated | N/A | 7 | Barts & The London NHS TrustOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02802124 | Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma | terminated | N/A | 30 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT05184283 | Utilization of MAsS in Patients Undergoing LT for HCC | terminated | — | 11 | Columbia UniversityOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT01897454 | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer | terminated | Phase 2 | 23 | Albert Einstein College of MedicineOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02649673 | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies | terminated | Phase 1 | 34 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02859064 | Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres | terminated | Phase 2 | 6 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04690855 | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer(TARA) | terminated | Phase 2 | 1 | Mylin A. Torres, MDOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | terminated | Phase 1 | 10 | Leap Therapeutics, Inc.INDUSTRY | 1 | Nov 30, 2023 | clinicaltrials |
| NCT03641287 | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors | terminated | N/A | 64 | University of WashingtonOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03867370 | Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 40 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03724409 | Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases | terminated | Early Phase 1 | 3 | Sandeep LaroiaOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT02963363 | Adapted Physical Activity for Breast Cancer HER2 Positive Patient(APACAN2) | terminated | N/A | 36 | Centre Jean PerrinOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT01690715 | Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in Patients With Hepatocellular Carcinoma Submitted to Surgery(HSL2012-06) | terminated | — | 50 | Hospital Sirio-LibanesOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT02285543 | A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients | terminated | Phase 2 | 10 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03618134 | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner | terminated | Phase 1 / Phase 2 | 19 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04329949 | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma(RELIANT) | terminated | Phase 3 | 43 | Corcept TherapeuticsINDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04565327 | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma | terminated | Phase 2 | 7 | Zhen Wang, MDOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT02127073 | Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer | terminated | Phase 2 | 8 | Montefiore Medical CenterOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | terminated | Phase 3 | 341 | PfizerINDUSTRY | 19 | Oct 30, 2023 | clinicaltrials |
| NCT03995667 | Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer | terminated | Phase 2 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT04300140 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 72 | Aravive, Inc.INDUSTRY | 1 | Oct 30, 2023 | clinicaltrials |
| NCT04983407 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 34 | Aravive, Inc.INDUSTRY | 1 | Oct 30, 2023 | clinicaltrials |
| NCT01041027 | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer | terminated | Phase 2 | 31 | Albert Einstein College of MedicineOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT01307956 | Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer | terminated | Phase 2 | 11 | University of NebraskaOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT03649841 | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer | terminated | Phase 2 | 10 | University of WashingtonOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT05329545 | Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)(UP-NEXT) | terminated | Phase 3 | 20 | Mersana TherapeuticsINDUSTRY | 3 | Oct 26, 2023 | clinicaltrials |
| NCT04235660 | Y90 Radiation Segmentectomy vs SBRT for HCC(SBRT vs Y90) | terminated | N/A | 2 | Indiana UniversityOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT02383433 | Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer | terminated | Phase 2 | 2 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 23, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Feb 29, 2024source: clinicaltrials